Israel - Tiếng Anh - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 2000 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

Israel - Tiếng Anh - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 250 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

Israel - Tiếng Anh - Ministry of Health

bayer israel ltd - recombinant human coagulation factor viii - powder and solvent for solution for injection - recombinant human coagulation factor viii 500 iu - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). kovaltry can be used for all age groups.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 1000 u;  ;   - powder for injection with diluent - 1000 u - active: factor viii inhibitor bypassing fraction 1000 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 2500 u;  ;   - powder for injection with diluent - 2500 u - active: factor viii inhibitor bypassing fraction 2500 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

takeda new zealand limited - factor viii inhibitor bypassing fraction 500 u;  ;   - powder for injection with diluent - 500 u - active: factor viii inhibitor bypassing fraction 500 u     excipient: sodium chloride sodium citrate dihydrate water for injection - feiba nf is indicated for treatment of haemorrhage and to cover surgical interventions in: · haemophilia a patients with factor viii inhibitors · haemophilia b patients with factor ix inhibitors. feiba nf is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in haemophilia a subjects with inhibitors experiencing >/= 12 bleeding episodes per year. prophylaxis with feiba nf is recommended for patients with high titer (>5bu) inhibitor or low titer (<5 bu) inhibitor, refractory to increased dosing with fviii or fix.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - factor viii, human 1000 [iu] (equal to, or less than 22 mg protein);  ;   - powder for injection - 1000 iu - active: factor viii, human 1000 [iu] (equal to, or less than 22 mg protein)     excipient: calcium chloride dihydrate fibrinogen glycine polysorbate 80 sodium chloride sodium citrate dihydrate tributyl phosphate water for injection - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand's disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - factor viii, human 250 [iu] (as human plasma coagulation factor viii. less than or equal to 5.5 mg total protein.);  ;   - powder for injection - 250 iu - active: factor viii, human 250 [iu] (as human plasma coagulation factor viii. less than or equal to 5.5 mg total protein.)     excipient: calcium chloride dihydrate fibrinogen glycine polysorbate 80 sodium chloride sodium citrate dihydrate tributyl phosphate water for injection - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand's disease.

New Zealand - Tiếng Anh - Medsafe (Medicines Safety Authority)

octapharma new zealand ltd - factor viii, human 500 [iu] (total protein less than or equal to 11 mg);  ;   - powder for injection - 500 iu - active: factor viii, human 500 [iu] (total protein less than or equal to 11 mg)     excipient: calcium chloride dihydrate fibrinogen glycine polysorbate 80 sodium chloride sodium citrate dihydrate tributyl phosphate water for injection - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). this preparation does not contain von willebrand factor in pharmacologically effective quantities and is therefore not indicated in von willebrand's disease.

Malta - Tiếng Anh - Medicines Authority

baxter healthcare limited - factor viii inhibitor bypassing fraction 500 u - powder and solvent for solution for injection